What is the purpose of this trial?
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.
Dates: 09/25/2017 - 03/31/2018
Last Updated: 09/27/2017
Study HIC#: 2000020485